Aerin Medical Announces Positive Two-year Outcomes from the VATRAC Trial of VivAer®
Aerin Medical Inc. , a company dedicated to providing Ear, Nose and Throat (ENT) physicians with non-invasive solutions for the treatment of chronic nasal conditions, today announced that Rhinology Journal has published positive two-year outcomes from the VATRAC trial.
- Aerin Medical Inc. , a company dedicated to providing Ear, Nose and Throat (ENT) physicians with non-invasive solutions for the treatment of chronic nasal conditions, today announced that Rhinology Journal has published positive two-year outcomes from the VATRAC trial.
- Previously published three-month results of the randomized controlled trial demonstrated that treatment with VivAer was safe and superior to a sham procedure.1
This press release features multimedia. - View the full release here: https://www.businesswire.com/news/home/20240208997581/en/
Two-year outcomes from the VATRAC trial published in Rhinology Journal confirm that treatment with VivAer® resulted in significant and lasting improvements in nasal obstruction symptoms. - This publication adds to a deep dossier of clinical evidence for VivAer, with three separate studies now confirming multi-year durability.